Aflibercept
Aflibercept (Zaltrap, Sanofi Winthrop Industrie) has 1 EU-approved indication in 1 tumour type.
| Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|
| Colorectal cancer1 | |||
None | + irinotecan/5-fluorouracil/folinic acid (FOLFIRI) | 2L metastatic | After oxaliplatin-containing regimen (resistant to or progressed after) |
Full text of section 4.1 (therapeutic indications)
ZALTRAP in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy is indicated in adults with metastatic colorectal cancer (MCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen.
Label history
17 changes to the Zaltrap label since 2014, none of them to the indications. Newest first, in the words of EMA's record of each procedure.
Changes